Acta Scientific Nutritional Health

Research articleVolume 2 Issue 4

Therapeutics and Phytochemicals Activity Alterations Due to the NOD2-G908R Point Mutation In Vitro

Madharasi VA Pichai1,2, Pamela Murray3, Nishi Karunasinghe3 and Lynnette R Ferguson1,3*

1Discipline of Clinical Nutrition and Dietetics, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
2Department of Neurology, Los Angeles Biomedical Research Institute, UCLA-Habor medical center, California, USA
3Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand

*Corresponding Author: Lynnette R Ferguson, Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.

Received: March 05, 2018; Published: March 29, 2018

Citation: Lynnette R Ferguson., et al. “Therapeutics and Phytochemicals Activity Alterations Due to the NOD2-G908R Point Mutation In Vitro”. Acta Scientific Nutritional Health 2.4 (2018).

Abstract

  The nature of several of the genetic mutations in Inflammatory bowel disease (IBD) indicate that compounds that might be expected to have an anti-inflammatory effect might be altered due to some mutational impacts. Also, there is an increasing trend towards the use of complementary and alternative therapies by IBD patients, especially in pediatric cohorts, and many of these therapies contain phytochemicals and nutraceuticals. A reduction in colonic inflammation, whether through the use of a conventional pharmaceutical or a nutraceutical, and the differential impacts due to key mutations will help in understanding the therapeutic potential of drugs and phytochemicals in aiding IBD subjects with and without vital mutations. Therefore, we have utilized an In Vitroscreening assay that considers an anti-inflammatory response of the chemicals towards a pair of mammalian cell lines, one of which is functional in a key genetic region associated with IBD susceptibility and one of which carries the genetic variant. A representative range of pharmaceuticals and phytochemicals has been selected for comparative study. Results from this study indicated the effects of NOD2 mutation G908R in altering the impacts of some drugs and phytochemicals In Vitro. The effects of drugs Cyclosporin A, Methotrexate and phytochemicals Arctigenin, Glabridin, AKBA, Ellagic acid and Z-Guggulsterone were differentiated due to the NOD2-G908R mutation in this In Vitro analysis, while effects of other phytochemicals Triptolide, PEITC, Curcumin, Epigallocatechin-3-gallate and drugs prednisolone and Mesalamine were not significantly altered due to the NOD2-G908R mutation in this In Vitro study.

Keywords: NOD2-G908R; Methotrexate; Mutation; Phytochemicals; Mesalamine; Drugs

Copyright: © 2018 Lynnette R Ferguson., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Member In




News and Events

  • Submission Timeline
    Last date for submission of articles is July 25, 2019.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Papers of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US